and the 2Clinical Pharmacology Unit, Royal Bath Hospital, Harrogate SUMMARY An enzyme linked immunoassay (ELISA) for the collagen cross link, pyridinoline, has been developed using affinity purified antibodies, with a sensitivity down to about 0.1 ng of cross link. Measurements of urinary pyridinoline were made in patients with rheumatoid arthritis (RA), osteoarthritis (OA), and a control group showing no signs of joint disease. Expressed relative to creatinine values, pyridinoline was significantly increased in both RA and OA groups compared with controls: these differences were much larger than could be attributed to any age related effects or to changes in urinary creatinine concentrations. These findings were confirmed by analysis of a series of 24 h urine collections which showed that the total pyridinoline excretions were significantly higher in both RA and OA groups than in the controls. As pyridinoline is much more prevalent in cartilage than in bone collagen, measurement of this compound in urine may provide an index for monitoring the increased joint destruction that occurs in arthritic disease. 
Measurement of urinary hydroxyproline has been widely used as an index of collagen degradation' and has found applications in monitoring disorders involving excessive collagen resorption. The usefulness of this technique is, however, limited by the poor sensitivity caused by metabolism of large amounts of hydroxyproline in the liver. Further complications arise from the release of hydroxyproline at several stages of collagen biosynthesis and maturation, including procollagen degradation4 and processing.S Measurement of hydroxylysine glycosides was proposed as a more sensitive index,6
with the additional advantage that the relative amounts of mono-and disaccharide appeared to provide information on 
Patients and methods

PATIENTS
Patients with osteoarthrosis were selected because of definite radiological evidence of osteoarthrosis of the knee or hip, or both, and the clinical absence of gout or rheumatoid disease. Patients with rheumatoid arthritis were selected because they complied with the American Rheumatism Association criteria (classical or definite disease) and had definite radiological changes. All patients were undergoing inpatient treatment for their arthritis at a regional rheumatology centre in Harrogate. Patients were receiving a variety of analgesics or anti-inflammatory agents, or both, and some of the rheumatoid patients were also receiving second line therapy. Urine specimens were provided by the patients with the assistance of the nursing staff. The specimens were collected at various times during the day in an attempt to randomise the possible effects of physiotherapy on urinary pyridinoline. Paired specimens were separated by an interval of three to five days. No attempt was made to keep drug therapy constant during this interval. For the major part of this study the control group comprised hospitalised patients showing no clinical or biochemical evidence of abnormal muscle metabolism or of joint disease. In a subsequent study, where 24 h urine collections were made, the controls were normal volunteers of similar ages to those of additional RA and OA groups selected according to the criteria described previously. After preliminary experiments to determine the conditions of hydrolysis necesssary for complete release of pyridinoline, urine samples (1-0 ml) were hydrolysed in 3 M HCl at 107°C for 16 hours. After most of the HCI had been removed in a vacuum desiccator over solid NaOH the samples were redissolved in water, any insoluble material centrifuged down, and the supernatant again evaporated to dryness. The residues were dissolved in PBSTween and were diluted with the same buffer so that aliquots (0-1 ml) used for the assay corresponded to between 5 and 50 [LI of urine.
STATISTICAL PROCEDURES
Analysis of differences between groups in pyridinoline/creatinine ratios employed the Mann-Whitney U test.
Results
As shown by a typical inhibition ELISA with standards ( Fig. 1 ) the detection limit of the assay was approximately 0 1 ng of pyridinoline. Tests with hydroxylysine, desmosines, and related pyridinium and amino acid derivatives showed less than 0-25% cross reaction with the antibody. In addition, the slope of the line generated by analysis of serial dilutions of a hydrolysed urine sample was similar to that of the standard curve, indicating that the antibody affinity for the measured compound was the same as for pyridinoline.
Preliminary experiments using different concentrations of acid for hydrolysis showed that full release of pyridinoline from urine was achieved with 3 M HCl, and these conditions were used for the present study. Some free cross link was detected without hydrolysis, but this did not represent a consistent proportion of that measured in the hydrolysates (see 'Discussion').
Details of the three patient groups used for the major study are given in Table 1 and creatinine levels. Investigation of the possibility that the pyridinoline/creatinine ratio was affected by changes in the denominator showed that there was no significant difference in creatinine levels between the control and RA groups; the patients with OA, however, had lower creatinine levels than the controls (p0-01), though this difference is unlikely to account fully for the observed increase in pyridinoline/creatinine ratio. A further study in which 24 h urine collections were analysed confirmed that the total urinary pyridinoline excretions were significantly higher in both the RA and OA groups than in the control group (Table 2) . In this second series of experiments creatinine levels in the patients with OA were lower than in the other two groups, though these results were based on relatively small numbers of patients. The differences in total pyridinoline excretions between the RA and OA groups were not statistically significant.
Discussion
The results of this preliminary study show significantly increased amounts of pyridinoline in the urine of patients with arthritic disease. This conclusion was valid not only when the results were expressed relative to creatinine levels but also as total excretion of the cross link per day. Aberrations due to changes in creatinine levels can, therefore, be largely discounted, and, in particular, the lack of correlation between pyridinoline and creatinine precludes the possibility that kidney dysfunction contributed to the increased pyridinoline excretion.
In general both patients with RA and OA showed similar increases in the pyridinoline/creatinine ratio, an index which appears therefore to reflect joint destruction, a process common to both types of disorder. 
